Sector ratings Vanda Pharmaceuticals Inc.

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 15/06/2026 BST			5-day change	1st Jan Change
5.880 ^USD	+0.17%		-2.49%	-33.33%

05-07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
05-06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation	Visibility
VANDA PHARMACEUTICALS INC.	353M	-	CCC	-	-
ARGENX SE	56.42B		A
WUXI APPTEC CO., LTD.	44.54B		AAA
BIONTECH SE	22.9B	-	-	-	-
INSMED INCORPORATED	21.21B	-	A	-	-
WUXI BIOLOGICS (CAYMAN) INC.	16.4B		AAA
GENMAB A/S	15.4B		A
EXELIXIS, INC.	13.35B		BB
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	12.36B	-	AA	-	-
PHARMAESSENTIA CORPORATION	11.15B		AA
MADRIGAL PHARMACEUTICALS, INC.	11.08B	-	B	-	-
SUMMIT THERAPEUTICS INC.	10.87B	-	-	-	-
AKESO, INC.	10.82B		B
ARROWHEAD PHARMACEUTICALS, INC.	10.5B	-	BB	-	-
NUVALENT, INC.	9.74B	-	CCC	-	-
CYTOKINETICS, INCORPORATED	9.52B	-	AA	-	-
REMEGEN CO., LTD.	7.93B		-
IMMUNITYBIO, INC.	7.44B	-	CCC	-	-
SAMSUNG EPIS HOLDINGS CO., LTD.	7.33B		AA			-
BIOCON LIMITED	7.13B		B
Average	15.32B		A
Weighted average by Cap.			A